BioHarvest Sciences initiated with a Buy at Roth Capital

Roth Capital analyst Sean McGowan initiated coverage of BioHarvest Sciences (BHST) with a Buy rating and $10 price target The firm believes the company’s botanical synthesis platform will drive “significant” revenue growth in the coming years. BioHarvest’s annual cash flow should turn sustainably positive beginning in 2027, the analyst tells investors in a research note. Roth cites the company’s “rapid growth, expanding footprint and emerging profitability” for the Buy rating.